Trevi Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
TRVI$15.31+6.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Amounts in thousands, except share and per share amounts)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $34,097 | $32,397 |
| Marketable securities | 73,525 | 50,574 |
| Prepaid expenses | 939 | 3,621 |
| Other current assets | 867 | 955 |
| Total current assets | 109,428 | 87,547 |
| Operating lease right-of-use assets | 915 | 1,137 |
| Finance lease right-of-use assets | 157 | 206 |
| Property, equipment and leasehold improvements, net | 157 | 216 |
| Other non-current assets | 243 | 297 |
| Total assets | $110,900 | $89,403 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,414 | $1,809 |
| Accrued expenses | 6,810 | 3,709 |
| Operating lease liabilities | 254 | 184 |
| Finance lease liabilities | 31 | 122 |
| Total current liabilities | 10,509 | 5,824 |
| Operating lease liabilities | 747 | 1,001 |
| Finance lease liabilities | — | 31 |
| Total liabilities | 11,256 | 6,856 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value; 5,000,000 shares authorized at December 31, 2024 and December 31, 2023; no shares issued or outstanding at December 31, 2024 and December 31, 2023. | — | — |
| Common stock: $0.001 par value; 200,000,000 shares authorized at December 31, 2024 and December 31, 2023; and 93,602,631 and 68,283,699 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively. | 94 | 68 |
| Additional paid-in capital | 386,534 | 321,642 |
| Accumulated other comprehensive income (loss) | 61 | (29) |
| Accumulated deficit | (287,045) | (239,134) |
| Total stockholders’ equity | 99,644 | 82,547 |
| Total liabilities and stockholders’ equity | $110,900 | $89,403 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.